Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer
Molecular Cancer Therapeutics (2014) - Comments
pubmed: 24448822  doi: 10.1158/1535-7163.mct-13-0199  issn: 1538-8514  issn: 1535-7163 

Maoyong Fu, Erin L. Maresh, Gustavo F. Helguera, Meagan Kiyohara, Yu Qin, Negin Ashki, Tracy R. Daniels-Wells, Najib Aziz, Lynn K. Gordon, Jonathan Braun, Yahya Elshimali, Robert A. Soslow, Manuel L. Penichet, Lee Goodglick, Madhuri Wadehra